Key result
NT-proBNP-guided assessment cuts costs by ~$1000 and increases QALYs vs usual care for T2DM in China.
Why the study?
Heart failure affects up to 40% of patients with T2DM, and although NT-proBNP effectively assesses heart failure risk, its economic value in China is unclear.
Does NT-proBNP-guided heart failure risk assessment improve health outcomes and reduce costs compared to usual care in patients with T2DM in China?
Does NT-proBNP-guided heart failure risk assessment improve health outcomes and reduce costs compared to usual care in patients with T2DM in China?
NT-proBNP-guided HF risk assessment is a cost-saving strategy for patients with T2DM in China, reducing both HF cases and healthcare costs.
Answers are grounded in this paper and cite their sources.
May support cost-saving NT-proBNP guidance in Chinese T2DM; leaves open prospective validation before practice change.
AIMS: Heart failure (HF) affects up to 40 % of patients with type 2 diabetes mellitus (T2DM), imposing significant clinical and economic burdens. N-terminal pro-B-type natriuretic peptide (NT-proBNP) effectively assesses HF risk, but its economic value in China is unclear. METHODS: This study evaluated the cost-effectiveness of three HF risk assessment strategies in patients with T2DM: NT-proBNP-guided assessment (using a cut-off of ≥125 pg/mL), usual care in China, and Systematic COronary Risk Evaluation (SCORE). A decision tree and Markov model with 1-year cycles simulated lifetime direct medical costs (given in United States dollars [US$]) and health outcomes in patients with T2DM aged ≥40 years from a Chinese healthcare perspective. High-risk patients received SGLT2 inhibitors plus standard of care. RESULTS: Compared with usual care, the NT-proBNP-guided strategy was cost-saving, reducing costs by US$1002.73 while increasing QALYs by 0.055 per patient. It was also less costly and more effective than the SCORE strategy. Probabilistic sensitivity analysis confirmed the robustness of this finding, demonstrating a 96.9 % probability of the NT-proBNP strategy being cost-saving versus usual care. CONCLUSIONS: NT-proBNP is a dominant and robust cost-saving strategy for HF risk assessment in patients with T2DM in China, reducing both HF cases and associated healthcare costs.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) studied this question. NT-proBNP-guided assessment reduced costs by US$1002.73 and increased QALYs by 0.055 compared to usual care in patients with T2DM in China.
Synapse has enriched 10 related papers. Consider them for comparative context: